Application note: Cell-Based Therapies – Be on the Safe Side
Posted: 8 August 2019 | Sartorius | No comments yet
This Application note discusses how you can obtain on-time QC results within three hours to ensure your patient’s safety. It details the Microsart® ATMP Mycoplasma (a rapid real-time PCR mycoplasma detection kit for testing ATMPs) and the Microsart® ATMP Bacteria (for the sterility testing of cell culture samples including ATMPs).
Related content from this organisation
- Enhancing efficiency and economics in process development and biotherapeutics
- Pharmaceutical membrane filtration market to value $10 billion by 2025
- Cell line development services market to value $2.4 billion by 2030
- Microbial air sampler market to value $545mn by 2028
- Pharmaceutical QC market to value $9,700mn by 2027